Palbociclib Gains HER2+ Breast Cancer Maintenance Indication

by admin | Jun 25, 2026 | Health

Spread the love

Palbociclib is now the first CDK4/6 inhibitor approved for metastatic disease regardless of HER2 status.
Medscape Medical News

← Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas Mirvetuximab Fails to Boost Survival in Platinum-Eligible OC →

Written By

Written by Albert Pham, News Curator and Blogger

AI Startup Red Queen Bio Uses Artificial Intelligence to Prepare for a Future Pandemic

Sep 28, 2026 | albertpham, Economy_finances, Health, Technology

Red Queen Bio is using AI to design antibody drugs against novel pathogens, highlighting the growing role of artificial intelligence in pandemic preparedness and biotech.

Harvard, MIT Professors Move to Canada Amid U.S. Research Funding Cuts

Sep 25, 2026 | albertpham, Economy_finances, Health, Politics

Harvard and MIT professors are moving to Canadian universities as Canada invests billions to attract global researchers amid U.S. research funding uncertainty.

Americans Could Lose Access to Cheaper Canadian Prescription Drugs

Sep 22, 2026 | albertpham, Economy_finances, Health

U.S. customs changes could restrict Americans’ access to cheaper prescription drugs from Canada and other foreign pharmacies starting in October.

Palbociclib Gains HER2+ Breast Cancer Maintenance Indication

Written By

Related Posts

AI Startup Red Queen Bio Uses Artificial Intelligence to Prepare for a Future Pandemic

Harvard, MIT Professors Move to Canada Amid U.S. Research Funding Cuts

Americans Could Lose Access to Cheaper Canadian Prescription Drugs

0 Comments

Explore More

Connect With Us

Quick Links

Legal

Stay Updated